A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples

2010152 citationsJournal Articlegold Open Access

Authors

Gillian Ellison · AstraZeneca (United Kingdom)

Emma Donald · AstraZeneca (United Kingdom)

Gael McWalter · AstraZeneca (United Kingdom)

Lucy Knight · IQVIA (United Kingdom)

Lynn M. Fletcher · AstraZeneca (United Kingdom)

James Sherwood · AstraZeneca (United Kingdom)

Mireille Cantarini

Abstract

ARMS was more sensitive and robust at detecting defined somatic mutations than DNA sequencing on clinical samples where the predominant sample type was FF-PET.

Topics & Keywords

Cancer Genomics and Diagnostics Lung Cancer Treatments and Mutations vaccines and immunoinformatics approaches

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Experimental & Clinical Cancer Research

Volume 29, Issue 1, pp. 132-132

DOI: 10.1186/1756-9966-29-132

Field-Weighted Citation Impact: 4.18